December 28, 2023 11:04 AM EST
R&D
Manufacturing

Zealand drug hit with CRL for ul­tra-rare dis­ease amid man­u­fac­tur­ing con­cerns, plans to re­sub­mit in 2024

Ayisha Sharma

News Reporter

The FDA re­ject­ed Zealand Phar­ma’s glucagon re­cep­tor ag­o­nist in con­gen­i­tal hy­per­in­sulin­ism (CHI) af­ter iden­ti­fy­ing prob­lems at a third-par­ty man­u­fac­tur­ing site.

The com­pa­ny said it re­mains …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times